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Abstract
Background Quantifying the activity of the adrenomedullin system might help to monitor and guide treatment in acute heart 
failure (AHF) patients. The aims were to (1) identify AHF patients with marked benefit or harm from specific treatments at 
hospital discharge and (2) predict mortality by quantifying the adrenomedullin system activity.
Methods This was a prospective multicentre study. AHF diagnosis and phenotype were centrally adjudicated by two inde-
pendent cardiologists among patients presenting to the emergency department with acute dyspnoea. Adrenomedullin system 
activity was quantified using the biologically active component, bioactive adrenomedullin (bio-ADM), and a prohormone 
fragment, midregional proadrenomedullin (MR-proADM). Bio-ADM and MR-proADM concentrations were measured in 
a blinded fashion at presentation and at discharge. Interaction with specific treatments at discharge and the utility of these 
biomarkers on predicting outcomes during 365-day follow-up were assessed.
Results Among 1886 patients with adjudicated AHF, 514 patients (27.3%) died during 365-day follow-up. After adjusting 
for age, creatinine, and treatment at discharge, patients with bio-ADM plasma concentrations above the median (> 44.6 pg/
mL) derived disproportional benefit if treated with diuretics (interaction p values < 0.001). These findings were confirmed 
when quantifying adrenomedullin system activity using MR-proADM (n = 764) (interaction p values < 0.001). Patients with 
bio-ADM plasma concentrations above the median were at increased risk of death (hazard ratio 1.87, 95% CI 1.57–2.24; 
p < 0.001). For predicting 365-day all-cause mortality, both biomarkers performed well, with MR-proADM presenting an 
even higher predictive accuracy compared to bio-ADM (p < 0.001).
Conclusions Quantifying the adrenomedullin’s system activity may help to personalise post-discharge diuretic treatment 
and enable accurate risk-prediction in AHF.
Keywords Dyspnoea · Acute heart failure · Adrenomedullin · Diuretics
Introduction
Acute heart failure (AHF) is the most common cause of hos-
pitalisation in patients 50 years or older, and it is still associ-
ated with unacceptably high mortality and morbidity [1, 2], 
with up to 30% of patients dying within 1 year after hospital 
discharge [1]. The poor outcomes of patients with AHF are 
at least in part due to incomplete understanding of the patho-
physiology of AHF, as well as uncertainty in defining the 
intensity of both in-hospital and immediate post-discharge 
management resulting from a lack of high-quality evidence 
for treatments in these clinical settings [1, 3].
The use of cardiovascular biomarkers may contrib-
ute to addressing some of these unmet clinical needs. For 
instance, the clinical introduction of natriuretic peptides 
quantifying haemodynamic cardiac stress has substantially 
improved early and accurate diagnosis of AHF [4–7]. Novel 
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cardiovascular biomarkers may help to unravel distinct 
pathophysiological AHF phenotypes with marked benefits 
(or harm) from specific treatments and allow personalised 
treatment and management. Initial pilot studies suggested 
that the adrenomedullin system may allow quantifying sys-
temic microvascular dysfunction and the associated mor-
tality risk [8–13]. Specifically, adrenomedullin secretion is 
increased upon volume overload and is expected to function 
as a compensatory mechanism maintaining barrier func-
tion, thus hindering tissue congestion [14]. In this context, 
a clinical phase-2 trial with a monoclonal antibody against 
the N-terminal end of adrenomedullin (adrecizumab), 
which increases the plasma concentrations of bioactive 
adrenomedullin, has recently been initiated in AHF patients 
(NCT04252937) [15]. Furthermore, since residual conges-
tion in AHF is associated with adverse outcomes, and evi-
dence from large clinical trials guiding the use of diuretics 
is generally lacking, the ability of adrenomedullin to reflect 
tissue congestion may be particularly useful for this purpose 
[16].
In an international multicentre study, we aimed to use 
two complimentary biochemical windows to quantify the 
activity of the adrenomedullin system to: (1) identify AHF 
patients with marked benefit or harm from specific treat-
ments at hospital discharge, and (2) predict mortality. The 
first biomarker used was midregional proadrenomedullin 
(MR-proADM), a stable precursor that does not distinguish 
between biologically active amidated adrenomedullin and 
the non-functional adrenomedullin variant containing a 
glycine-extended C-terminal residue [15]. The second bio-
marker was the biologically active form of adrenomedullin, 
bioactive adrenomedullin (bio-ADM) [17].
Methods
Study design and adjudication of final diagnosis
The study sample included three prospective diagnostic 
cohorts of unselected AHF patients admitted after present-
ing with acute dyspnoea to the emergency department (ED) 
of the respective participating university hospitals in three 
countries using comparable methodology (United King-
dom, France, and Switzerland NCT01831115). Assessment 
and therapies for AHF, including diuretics, were provided 
according to guidelines and the discretion of attending phy-
sicians [6]. AHF was centrally adjudicated by two independ-
ent cardiologists in accordance with European Society of 
Cardiology guidelines [6]. Inclusion was independent of 
renal function, although patients with terminal renal fail-
ure on renal replacement therapy were excluded. Patients 
were followed for at least 1 year. This study was performed 
according to the principles of the Declaration of Helsinki 
and ethics approval was granted from the respective research 
ethics committees. All patients provided written informed 
consent. The authors designed the study, gathered, and ana-
lysed the data according to The TRIPOD Statement for stud-
ies reporting multivariable prediction models for individual 
prognosis (Supplemental Table 1), vouch for the data and 
analysis, wrote the paper, and decided to publish.
Plasma sampling
After obtaining signed informed consent, venous blood was 
drawn from recumbent patients and collected in tubes con-
taining ethylenediaminetetraacetic acid as anticoagulant. 
The interval for sample obtainment at admission was up 
to 4 h (Paris), 2 h (Basel), and 12 h (Leicester) after ED 
presentation. Bio-ADM and MR-proADM blood samples at 
hospital (acute ward) discharge were available for patients 
recruited in Basel and Leicester. Furthermore, due to fund-
ing as well as logistics reasons, MR-proADM measurements 
were available only in a subgroup of unselected patients. To 
maximise the generalisability of the findings and consider-
ing substantial variation in overall length of hospital stay 
and the availability of rehabilitation units among different 
countries, “hospital discharge” samples were obtained at 
discharge from the acute ward, prior to possible transfer to 
a rehabilitation unit. Plasma was stored at − 80 °C until 
blinded analysis in a central laboratory.
Imaging, renal function, haemoconcentration, 
and biomarker assays
Transthoracic echocardiography was performed using 
standard techniques and the left ventricular ejection frac-
tion (LVEF) was calculated using the biplane method 
of discs formula. According to the LVEF, patients were 
stratified as heart failure with preserved ejection fraction 
(HFpEF, LVEF ≥ 50%), mid-range ejection fraction (HFm-
rEF, LVEF 40–49), and reduced ejection fraction (HFrEF, 
LVEF < 40%). Imaging data were available for patients 
recruited in Leicester and Basel. Haemoconcentration was 
defined as an increase in at least three of the four haemocon-
centration-defining parameters (haemoglobin, haematocrit, 
albumin, and total protein) above admission values occur-
ring simultaneously at discharge, as described previously 
[18]. These parameters as well as clinical data on volume 
overload such as estimated jugular venous pressure, periph-
ery oedema, or third heart sound were only available in 
patients recruited in Basel. To determine plasma bio-ADM 
concentrations, a new double-monoclonal antibody sand-
wich immunoassay was used (sphingotec GmbH, Hennigs-
dorf, Germany). This immunoassay selectively detects the 
C-terminally amidated form of adrenomedullin. In healthy 
subjects, the median value was previously determined to be 
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24.7 pg/mL and the 99th percentile 43 pg/mL. The lower 
detection limit is 3 pg/mL, and intra- and interassay coef-
ficients were 5–10%, and 4–8%, respectively, in the above 
normal measuring range. The analytical assay sensitivity is 
2 ng/L [12, 19]. MR-proADM was measured using an auto-
mated sandwich chemiluminescence immunoassay on the 
KRYPTOR system (B·R·A·H·M·S AG, Hennigsdorf/Ber-
lin, Germany), with a quantification limit of 0.23 nmol/L, 
a within-run imprecision (coefficient of variation) of 1.9%, 
and a between-run imprecision (coefficient of variation) of 
9.8% [9, 20].
Outcome measures
The two co-primary objectives were: (1) identification of 
AHF phenotypes with disproportional benefit or harm from 
medical treatment at discharge in terms of all-cause mor-
tality during the 365-day follow-up. This was assessed by 
exploring interactions between bio-ADM plasma concentra-
tions and treatment with diuretics, angiotensin-converting-
enzyme (ACE) inhibitors or angiotensin receptor blockers 
(ARBs), beta blockers, and aldosterone-antagonists at dis-
charge. (2) Assessment of the prognostic accuracy of bio-
ADM for predicting all-cause mortality during the 365-day 
follow-up. The secondary objectives were defined as (1) 
and (2) with the combined outcome measure of all-cause 
mortality and AHF readmissions during follow-up. An 
additional aim was to directly compare bio-ADM with MR-
proADM in these indications. Furthermore, the incremental 
value of both biomarkers was assessed when added to the 
OPTIMIZE-HF clinical risk-score, established for predict-
ing up to 90-day all-cause mortality after hospitalisation for 
AHF [21]. Similarly, the independent predictive value of 
bio-ADM and MR-proADM was compared to the impact of 
haemoconcentration during hospitalisation [18].
Endpoints were ascertained blinded to biomarker data 
from hospital records and electronic databases. Patients who 
survived until discharge were followed for at least 365 days 
after the initial hospitalisation. Data on AHF readmissions 
were not available for patients from Paris (n = 225, 11% of 
the overall cohort).
Statistical analysis
The Kolmogorov–Smirnov test and visual inspection of 
the distribution of variables was used for testing normal-
ity. Continuous variables are presented as medians with 
interquartile range, and categorical variables as numbers 
and percentages. Comparisons between groups were made 
using Chi-square, Mann–Whitney U, and Kruskal–Wallis 
tests, as appropriate. Spearman’s rho was used to analyse 
correlations. One-way ANOVA and Eta test statistics were 
used to assess associations of categorical variables and 
continuous variables. All-cause mortality and its combina-
tion with AHF hospitalisations during follow-up were plot-
ted in Kaplan–Meier curves, and the log-rank test was used 
to assess differences between groups. The interaction p val-
ues between biomarker plasma concentrations and the pre-
defined subgroups according to medication at discharge were 
calculated in multivariable models using Cox proportional 
hazards analysis. Further adjustment of these multivariable 
models was imposed for clinical considerations: the vari-
ables age and creatinine plasma concentrations at discharge 
were incorporated, as both may affect the prescription of 
heart failure drugs and mortality. Severe renal dysfunction 
and hypotension (systolic blood pressure below 90 mmHg) 
were considered clinical criteria, possibly justifying tempo-
rary withdrawal of diuretic therapy. In a subgroup of patients 
with available haemoconcentration data, this parameter as 
well as bio-ADM or MR-proADM and variables from a 
validated risk model to predict 365-day all-cause mortal-
ity were entered in multivariable regression models [22]. 
Sensitivity analysis was performed after excluding patients 
discharged from acute wards to palliative care. Hazard ratios 
(HR) are presented with 95% confidence intervals (CI). The 
prognostic accuracy of bio-ADM and MR-proADM plasma 
concentrations were quantified using the area under the time-
dependent receiver-operating characteristic curves (AUC) 
and compared as described previously [23]. Furthermore, 
time-dependent receiver-operating characteristic curves 
were also used to assess the prognostic accuracy of the 
OPTIMIZE-HF risk-score alone and its combination with 
each biomarker. This was a post hoc analysis within prospec-
tive studies, and the sample size of the overall cohort was 
not determined specifically for this analysis [18]. No impu-
tation was performed for missing values. Patients without 
complete clinical follow-up were censored at the time of the 
last known contact. All hypothesis testing was 2-sided and 
after Bonferroni correction for multiple testing (16 tests for 
interactions for the primary endpoint of all-cause mortal-
ity) a p value ≤ 0.003 was considered significant. Statistical 




A total of 1886 AHF patients enrolled between March 
2006 and June 2015 were eligible for this analysis (Sup-
plemental Fig. 1); 37.9% were women and the median 
age was 78 years (Table 1); 34.8% patients had HFpEF, 
14.2% had HFmrEF, and 20.1% had HFrEF. Median bio-
ADM concentrations at admission were 44.6 pg/mL, being 
similar between women and men (p = 0.219). Bio-ADM 
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Table 1  Patient characteristics according to study site
ACE angiotensin-converting-enzyme, ARBs angiotensin receptor blocker, BMI body mass index, bio-ADM bioactive adrenomedullin, CAD coro-
nary artery disease, CCB calcium channel blockers, COPD chronic obstructive pulmonary disease, CKD chronic kidney disease, ED emergency 
department, HR heart rate, MR-proADM midregional proadrenomedullin, LV left ventricle, LVEDD left ventricular end diastolic diameter, NT-
proBNP N-terminal pro-B-type natriuretic peptide, PAD peripheral artery disease, SBP systolic blood pressure
*Data not available
All patients (n = 1886) Leicester (n = 862) Paris (n = 215) Basel (n = 809)
Demographics
 Age, years 78.0 (69.0–84.0) 77.0 (68.1–83.0) 76.0 (66.0–84.0) 79.0 (70.0–85.0)
 Female, gender, % 37.9 37.4 38.6 38.2
 BMI, kg/m2 27.4 (24.1–31.6) 31.4 (27.2–37.7) * 26.5 (23.5–30.1)
Clinical parameters at ED
 SBP, mmHg 134 (117–153) 134 (116–151) 135.0 (113–158) 135 (118–154)
 HR, beats/min 87 (72–105) 88 (73–105) 85 (69–105) 85 (71–103)
 LVEF, % 39 (27–52) 35 (25–47) * 44 (30–55)
 LVEDD, cm 5.3 (4.6–5.9) 5.3 (4.7–5.9) * 5.2 (4.6–5.9)
 LVESD, cm 4.2 (3.3–5.1) 4.4 (3.6–5.2) * 3.8 (3.0–4.9)
Medical history
 CKD, % 33.1 21.7 20.9 48.6
 Hypertension, % 69.7 58.6 64.2 82.9
 Dyslipidaemia, % 42.0 26.2 * 59.5
 Stroke or TIA, % 16.2 16.9 * 15.3
 Current or ex-smoker, % 55.4 48.0 * 63.7
 Atrial fibrillation, % 42.7 47.3 * 37.8
 PAD, % 10.6 5.3 * 16.4
 COPD, % 16.1 10.2 * 22.5
 Diabetes, % 32.0 34.6 29.3 30.0
Medication at presentation
 ACE inhibitors/ARB, % 61.5 57.0 * 66.3
 Beta blockers, % 53.6 44.2 * 63.8
 Aldosterone antagonists, % 13.1 12.5 * 13.7
 Loop diuretics, % 65.4 61.1 * 70.0
Medication at discharge
 ACE inhibitors/ARB, % 69.6 63.9 63.7 78.1
 Beta blockers, % 62.3 53.2 61.4 72.4
 Aldosterone antagonists, % 31.0 32.9 26.0 30.3
 Loop diuretics, % 85.0 81.3 78.1 91.1
Laboratory parameters at admission
 Haemoglobin, g/L 125.0 (111.0–138.0) 123.0 (109.0–137.0) * 126.0 (113.0–139.0)
 Sodium, mmol/L 139.0 (136.0–141.0) 138.0 (135.0–141.0) 137.0 (134.0–140.0) 139.0 (137.0–142.0)
 Potassium, mmol/L 4.3 (3.9–4.6) 4.4 (4.0–4.7) * 4.2 (3.8–4.5)
 Creatinine, μmol/L 111.0 (86.0–146.0) 113.0 (91.0–142.0) 115.0 (84.3–151.0) 107.0 (82.0–148.0)
 NT-proBNP, pg/mL 3094 (1468–6257) 2188 (984–4093) * 4914 (2411–9787)
 BNP, pg/mL 1244 (638–2376) * 1244 (638–2376) *
 Urea, mmol/L 9.2 (6.6–13.4) 8.9 (6.5–12.9) 9.4 (6.8–14.6) 9.6 (6.6–13.4)
 Bio-ADM, pg/mL 44.6 (30.2–69.2) 49.6 (33.8–81.2) 47.4 (33.8–82.8) 38.5 (26.3–57.4)
 MR-proADM, nmol/L 1.67 (1.20–2.42) 1.74 (1.30–2.69) 1.18 (1.04–1.78) 1.62 (1.16–2.23)
Laboratory parameters at discharge
 Creatinine, μmol/L 111.0 (88.0–147.0) 113.0 (92.0–146.5) * 108.0 (84.0–149.0)
 NT-proBNP, pg/mL 1963 (861–4335) 1544 (644–2888) * 2636 (1069–5844)
 Bio-ADM, pg/mL 37.0 (25.8–55.6) 45.6 (31.6–68.9) * 29.3 (20.0–41.6)
 MR-proADM, nmol/L 1.42 (1.03–2.00) 1.67 (1.16–2.24) * 1.28 (0.96–1.78)
Clinical Research in Cardiology 
1 3
and MR-proADM concentrations correlated moder-
ately (r = 0.639), and bio-ADM correlated less strongly 
with age, NT-proBNP, and serum creatinine versus MR-
proADM concentrations (Table 2). 
Survival analysis
During the 365-day follow-up, there were 514 deaths 
(27.3%). Mortality was comparable among sites (Supple-
mental Figs. 2 and 3). Patients who died during follow-up 
were older, had a lower body mass index, more often had 
a history of renal impairment, and lower initial systolic 
blood pressure and LVEF (Table 3). Notably, their bio-
ADM and MR-proADM plasma concentrations at admis-
sion and at hospital discharge were substantially higher 
compared to survivors.
Interaction with heart failure treatment 
at discharge
There were statistically significant interactions regarding 
mortality depending on MR-proADM or bio-ADM plasma 
concentrations at admission or discharge and prescription 
of diuretics at discharge (Supplemental Table 2). These 
interactions remained significant after adjusting for age, 
NT-proBNP and creatinine plasma concentrations at dis-
charge (Table 4). Overall, 276 (15%) patients were dis-
charged without prescription of diuretics (Supplemental 
Table 3). Among them, history of chronic kidney disease 
was less common as compared to those with diuretics 
prescription at discharge (26.5% vs 33.9%, p = 0.017). 
Similarly, treatment with diuretics prior to admission 
was less common (53.1% vs 67.2%, p < 0.001). Patients 
not receiving diuretics at discharge and with bio-ADM 
levels above the median presented much higher all-cause 
mortality (Fig. 1). Findings regarding 365-day all-cause 
mortality and AHF rehospitalisations were comparable 
(Supplemental Tables 4 and 5; Supplemental Figs. 4 and 
5). Furthermore, subgroup analyses according to LVEF 
groups suggested more pronounced interactions in patients 
with HFrEF (Supplemental Tables 6 and 7). 
Notably, no statistically significant interactions were pre-
sent between NT-proBNP plasma concentrations and medi-
cal therapies at discharge (Supplemental Tables 8 and 9). 
In-depth review of clinical characteristics of patients with 
bio-ADM concentrations above the median and without diu-
retics at discharge, who died during follow-up, showed that 
at acute ward discharge many did not have an established 
medical cause such as severe renal dysfunction or hypoten-
sion, possibly justifying withdrawal of diuretics (Supple-
mental Table 10).
Table 2  (A) Spearman’s rank correlation analysis between bio-ADM 
and MR-proADM and demographics, clinical characteristics, echo-
cardiographic parameters, and biomarkers; (B) Eta test statistics to 
assess association between bio-ADM and MR-proADM and clinical 
characteristics
(A) Bio-ADM MR-proADM NT-proBNP
Age, years
 Spearman’s rank (rs) − 0.058 0.264 0.217
  p value 0.012 < 0.001 < 0.001
  n 1885 764 1576
BMI, kg/m2
 Spearman’s rank (rs) 0.295 − 0.021 − 0.385
  p value < 0.001 .596 < 0.001
  n 1005 621 923
Pulse oximetry, %
 Spearman’s rank (rs) − 0.075 − 0.044 − 0.081
  p value 0.036 0.373 .031
  n 786 416 710
HR, bpm
 Spearman’s rank (rs) 0.001 − 0.068 − 0.012
  p value 0.981 0.063 0.643
  n 1814 755 1522
SBP, mmHg
 Spearman’s rank (rs) − 0.184 − 0.248 − 0.137
  p value < 0.001 < 0.001 < 0.001
  n 1815 750 1519
DBP, mmHg
 Spearman’s rank (rs) − 0.109 − 0.188 − 0.008
  p value < 0.001 < 0.001 0.769
  n 1811 750 1516
LV ejection fraction, %
 Spearman’s rank (rs) − 0.123 − 0.127 − 0.222
  p value < 0.001 0.003 < 0.001
  n 1302 542 1234
LVEDD, mm*
 Spearman’s rank (rs) 0.057 0.046 0.144
  p value 0.049 0.304 < 0.001
  n 1209 505 1153
Haemoglobin, g/L
 Spearman’s rank (rs) − 0.131 − 0.272 − 0.111
  p value < 0.001 < 0.001 < 0.001
  n 1567 728 1496
Sodium, mmol/L
 Spearman’s rank (rs) − 0.133 − 0.096 0.015
  p value < 0.001 .008 0.542
  n 1855 747 1557
Creatinine, μmol/L
 Spearman’s rank (rs) 0.365 0.639 0.327
  p value < 0.001 < 0.001 < 0.001
  n 1855 749 1561
NT-proBNP, pg/mL
 Spearman’s rank (rs) 0.089 0.477 –
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Prognostic accuracy of bio‑ADM and MR‑proADM
In 764 patients (41%), both MR-proADM and bio-ADM 
were measured. The prognostic accuracy for predicting all-
cause mortality and the combination of all-cause mortal-
ity or AHF rehospitalisations at 365 days, quantified by the 
AUC, was significantly higher for admission MR-proADM 
compared to bio-ADM (Fig. 2 and Supplemental Fig. 6; for 
both outcome measures: p < 0.001 at 90, 180, and 365 days). 
Patients with bio-ADM concentrations above the median at 
admission were at increased risk of 365-day all-cause mor-
tality (HR 1.87, 95% CI 1.57–2.24; p < 0.001). In the sub-
group analysis of patients with MR-proADM measurements 
at admission, plasma concentrations of this biomarker above 
the median (> 1.67 nmol/L) were associated with a higher 
365-day all-cause mortality (HR 3.88, 95% CI: 2.77–5.44; 
p < 0.001; Supplemental Fig. 7). The OPTIMIZE-HF risk-
score was calculated in 1706 patients (90%), showing signif-
icant improvement in prognostic accuracy when combined 
with bio-ADM or MR-proADM along 90 days of follow-up 
(Supplemental Figs. 8 and 9). Variables from a validated 
risk model to predict all-cause mortality at 365 days as well 
as haemoconcentration achieved during hospitalisation and 
bio-ADM or MR-proADM were entered in multivariable 
regression models (Supplemental Tables 10A and 10B). 
Notably, both bio-ADM and MR-proADM remained inde-
pendent predictors of 365-day all-cause mortality.
Sensitivity analysis
Sensitivity analysis excluding the subgroup of patients 
discharged from the acute ward to palliative care (n = 10) 
revealed similar findings as in the overall cohort (Supple-
mental Tables 11–17 and Supplemental Figs. 10–16).
Discussion
In this large international multicentre study, we used plasma 
concentrations of bio-ADM and MR-proADM to identify 
AHF phenotypes with disproportional benefit or harm from 
specific heart failure treatments at hospital discharge and to 
predict mortality. We report five major findings.
First, patients with bio-ADM concentrations above the 
median had much higher mortality if not treated with diuret-
ics at discharge. Second, medical reasons including severe 
renal dysfunction and/or hypotension which could possibly 
justify temporal withdrawal of diuretics were absent in most 
of these patients. This confirms the possible clinical utility 
of this marker to avoid medical errors such as the withdrawal 
of diuretics in patients who very likely derive benefits from 
these drugs. Third, increased bio-ADM concentrations were 
associated with increased risk of death at 365 days. Nota-
bly, bio-ADM remained an independent prognostic factor 
for all-cause mortality after adjusting for haemoconcentra-
tion, comorbidities, vital signs, and further biomarkers from 
a validated multivariable prediction model [22]. Fourth, 
comparison of the two biochemical methods assessing adre-
nomedullin system activity showed that MR-proADM was 
superior to bio-ADM in the prediction of death and/or AHF 
re-hospitalisation within 365 days. Fifth, both bio-ADM 
and MR-proADM improved the prognostic accuracy of the 
OPTIMIZE-HF clinical risk-score for predicting all-cause 
mortality within 90 days after AHF hospitalisation.
These findings extend and corroborate earlier studies 
investigating the importance of adrenomedullin in patients 
with acute dyspnoea, as well as efforts to personalise treat-
ment in AHF patients [9, 12, 13, 17, 24–27]. The observa-
tion that patients with high bio-ADM concentrations had 
much higher mortality rates if not treated with diuretics 
at discharge seems to have immediate clinical conse-
quences. In-depth review of the clinical characteristics of 
these patients indicates inappropriate clinical reaction to 
temporary worsening of renal function during AHF treat-
ment, as well as a lack of reassessment of eligibility for 
diuretic therapy after appropriate temporal withdrawal 
Table 2  (continued)
(A) Bio-ADM MR-proADM NT-proBNP
 p value < 0.001 < 0.001
 n 1576 699
MR-proADM, nmol/L
 Spearman’s rank (rs) 0.639 –




 Eta squared (η2) 0.011 0.047 < 0.001
  p value 0.004 < 0.001 0.887
  n 728 396 651
Third heart sound (S3)*
 Eta squared (η2) 0.003 0.005 < 0.001
  p value 0.151 0.151 0.822
  n 756 406 681
Peripheral oedema*
 Eta squared (η2) 0.053 0.055 0.001
  p value < 0.001 < 0.001 0.473
  n 792 421 711
Correlation was calculated with measurements obtained on admission
bio-ADM bioactive adrenomedullin, BMI body mass index, DBP 
diastolic blood pressure, LV left ventricle, LVEDD left ventricular 
end diastolic diameter, MR-proADM midregional proadrenomedul-
lin, SBP systolic blood pressure, JVP jugular venous pressure, MR-
proADM midregional proadrenomedullin
*Data available only for patients from Basel
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Table 3  Patient’s characteristics 
according to survival status at 
365 days
ACE angiotensin-converting-enzyme, ARBs angiotensin receptor blocker, BMI body mass index, bio-ADM 
bioactive adrenomedullin, CAD coronary artery disease, CCB calcium channel blockers, COPD chronic 
obstructive pulmonary disease, CKD chronic kidney disease, ED emergency department, HR heart rate, 
MR-proADM midregional proadrenomedullin, LVEF left ventricular ejection fraction, LVEDD left ventric-
ular end diastolic diameter, NT-proBNP N-terminal pro-B-type natriuretic peptide, PAD peripheral artery 
disease, SBP systolic blood pressure
Dead at 365 days (n = 514) Alive at 365 days (n = 1372) p value
Demographics
 Age, years 81.0 (75.0–87.0) 76.5 (67.0–83.0) < 0.001
 Female, gender, % 37.0 38.2 0.684
 BMI, kg/m2 24.9 (21.8–28.4) 28.1 (24.6–32.8) < 0.001
Clinical parameters at ED
 SBP, mmHg 126 (110–145) 137 (120–155) < 0.001
 HR, beats/min 85 (72–101) 87 (72–105) 0.159
 LV ejection fraction, % 35 (24–49) 40 (29–54) < 0.001
 LVEDD, cm 5.3 (4.6–6.1) 5.2 (4.6–5.9) 0.313
 LVESD, cm 4.2 (3.4–5.2) 4.2 (3.3–5.0) 0.326
Medical history
 CKD, % 44.3 28.9 < 0.001
 Hypertension, % 67.7 70.4 0.280
 Dyslipidaemia, % 40.7 42.4 0.560
 Stroke or TIA, % 21.3 14.3 < 0.001
 Current or ex-smoker, % 57.5 54.6 0.330
 PAD, % 13.0 9.7 0.065
 Atrial fibrillation, % 41.4 43.1 0.568
 COPD, % 17.9 15.5 0.260
 Diabetes, % 31.7 32.1 0.911
Medication at presentation
 ACE inhibitors or ARB, % 59.2 62.3 0.284
 Beta blockers, % 52.1 54.1 0.511
 Aldosterone antagonists, % 16.9 11.7 0.006
 Loop diuretics, % 77.3 61.0 < 0.001
Medication at discharge
 ACE inhibitors or ARB, % 51.6 76.3 < 0.001
 Beta blockers, % 45.8 68.3 < 0.001
 Aldosterone antagonists, % 25.7 33.0 0.003
 Loop diuretics, % 75.8 88.3 < 0.001
Laboratory parameters at admission
 Haemoglobin, g/L 120 (108–132) 127 (113–139) < 0.001
 Sodium, mmol/L 138 (134–141) 139 (136–141) < 0.001
 Potassium, mmol/L 4.4 (3.9–4.8) 4.2 (3.9–4.6) 0.006
 Creatinine, μmol/L 132 (100.0–179.0) 105.0 (83.0–134.0) < 0.001
 Urea, mmol/L 12.3 (8.7–17.7) 8.4 (6.2–11.7) < 0.001
 NT-proBNP, pg/mL 4723.0 (2360–9029) 2629.0 (1259.0–5346) < 0.001
 BNP, pg/mL 1897 (810–3036) 1120 (605–2128) 0.009
 Bio-ADM, pg/mL 57.2 (35.3–94.3) 41.5 (28.8–62.0) < 0.001
 MR-proADM, nmol/L 2.32 (1.68–3.07) 1.50 (1.14–2.14) < 0.001
Laboratory parameters at discharge
 Creatinine, μmol/L 132.0 (100.0–191.0) 107.0 (85.0–135.0) < 0.001
 NT-proBNP, pg/mL 3327 (1678–8348) 1659 (686–3417) < 0.001
 Bio-ADM, pg/mL 46.7 (29.0–72.5) 34.74 (25.2–51.7) < 0.001
 MR-proADM, nmol/L 1.79 (1.45–2.77) 1.29 (0.99–1.83) < 0.001
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when arterial hypovolemia is considered the most likely 
cause of the absence of diuretic therapy at discharge [18, 
28, 29]. Whenever medical reasons possibly justifying 
temporal withdrawal of diuretics, such as severe renal 
dysfunction or hypotension, are no longer present at dis-
charge and in the vulnerable transition period immediately 
after discharge, reinstitution of diuretics seems to have 
major importance particularly in patients identified to be 
at very high risk of death by elevated bio-ADM concen-
trations [17, 30]. The value of bio-ADM in this setting 
is reinforced by the challenge to document euvolemia in 
hospitalised AHF patients [12]. As therapy for AHF at 
Table 4  Interaction p values in multivariable models using Cox proportional hazard analysis for predicting 365-day all-cause mortality including 
age, bio-ADM or MR-proADM, NT-proBNP at discharge, creatinine at discharge, and medication at discharge
ACE angiotensin-converting-enzyme, ARBs angiotensin receptor blocker, bio-ADM bioactive adrenomedullin, MR-proADM midregional proad-
renomedullin, NT-proBNP N-terminal pro-B-type natriuretic peptide
The bold p values are the ones considered significant, as reported in the Methods section: All hypothesis testing was 2-sidedand after Bonferroni 
correction for multiple testing (16 tests for interactions for the primary endpoint of all-cause mortality) a pvalue ≤ 0.003 was considered signifi-
cant. Please include the footnote: The bold p values (≤ 0.003) are considered significant.
Diuretics ACE inhibitors or ARB Beta blockers Aldosterone 
antagonists
lg bio-ADM at admission, pg/mL < 0.001 0.104 0.541 0.512
lg bio-ADM at discharge, pg/mL < 0.001 0.008 0.609 0.354
lg MR-proADM at admission, nmol/L 0.112 0.404 0.724 0.141
lg MR-proADM at discharge, nmol/L 0.002 0.225 0.969 0.381
Fig. 1  Mortality stratified according to bio-ADM and MR-pro-ADM 
concentration and the use of diuretics at discharge: A bio-ADM at 
presentation (n = 1844); B MR-proADM at presentation (n = 738); 
C bio-ADM at discharge (n = 997); D MR-proADM at discharge 
(n = 438). ACE angiotensin-converting-enzyme, ARBs angiotensin 
receptor blocker, bio-ADM bioactive adrenomedullin, MR-proADM 
midregional proadrenomedullin
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discharge often remains unchanged for several weeks and 
even months after discharge [1, 31], over-restrictive use 
of diuretics at this critical time point seems to have detri-
mental consequences for patients.
The statistically significant interaction of bio-ADM and 
MR-proADM with benefits from diuretics at discharge is 
well in line with recent evidence from a large international 
study characterising bio-ADM concentrations as a quantita-
tive marker of residual congestion in heart failure [12, 30]. 
Interestingly, the link between bio-ADM and residual tissue 
congestion and/or benefit from diuretics after discharge seems 
to be stronger compared to that for NT-proBNP, which mainly 
reflects increased left ventricular filling pressures and intra-
vascular volume overload [12]. This might be related to the 
important role of the adrenomedullin system in maintaining 
endothelial barrier function through regulation of the cortical 
actin formation in endothelial cells [15, 32, 33]. In vitro anal-
ysis showed that dysfunction of the adrenomedullin system 
leads to enhanced vascular permeability, and subsequently, 
pronounced oedema [33]. Accordingly, the unique ability of 
adrenomedullin to reflect this specific pathophysiological 
pathway in AHF could explain its incremental value to the 
established OPTIMIZE-HF clinical risk-prediction score [21].
The reason why these two biochemical approaches pro-
viding insight into the adrenomedullin system showed differ-
ent results in the prediction of death and in the identification 
of patients who would most benefit from diuretic therapy at 
discharge remains largely unknown. The biological active 
bio-ADM was superior in the latter aspect as not only dis-
charge, but already admission concentrations allowed the 
identification of patients with particular benefit from long-
term diuretic therapy. In contrast, MR-proADM was superior 
in predicting death which might be explained by the stronger 
correlation of MR-proADM with age and creatinine values 
compared to bio-ADM.
The current study has several limitations. First, our find-
ings were based on a large number of patients prospectively 
enrolled and hospitalised in three European countries. Fur-
ther research is warranted to validate our findings in other 
European and non-European populations. Second, our results 
cannot be extrapolated to patients with terminal renal fail-
ure undergoing long-term haemodialysis, because they were 
excluded. Third, although patients were enrolled prospec-
tively at all three sites, some variables including biomarker 
measurements at discharge were not available for patients 
enrolled in Paris. Fourth, data on dose of diuretics as well as 
doses of guidelines directed medical treatment for chronic 
heart failure was not available. Fifth, we could not assess 
the possible interaction between bio-ADM and MR-proADM 
concentrations and sacubitril/valsartan, as this drug was not 
yet in clinical use at patients’ enrolment. Sixth, despite in-
depth review of the individual patient’s characteristics includ-
ing severe renal dysfunction and/or hypotension, the final 
reasons why AHF patients were not prescribed with diuret-
ics at discharge cannot be established. Seventh, statistically 
significant interaction does not prove causality. Therefore, 
only a randomised controlled intervention study can prove 
improved outcomes with the use of diuretics post-discharge 
in AHF patients guided by adrenomedullin system activity.
In conclusion, quantification of adrenomedullin system 
activity seems to enable accurate risk-prediction in AHF 
patients and identify inadequate decongestion prior to dis-
charge, thereby has the potential to facilitate personalised 
post-discharge diuretic treatment.
Supplementary Information The online version contains supplemen-
tary material available at https:// doi. org/ 10. 1007/ s00392- 021- 01909-9.
Fig. 2  Time-dependent ROC 
curves describing the prognos-
tic performance of bio-ADM 
and MR-proADM to predict 
death during 365-day follow-up 
(n = 764). AUC of ROC curve: 
area under the time-dependent 
receiver-operating characteris-
tic curve. bio-ADM bioactive 
adrenomedullin, MR-proADM 
midregional proadrenomedullin
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